

A Review on Acute Myeloid Leukaemia

Maithri Gundaram*

National Institute of Pharmaceutical Education & Research, Kolkata, India

***Corresponding author:** Maithri Gundaram, National Institute of Pharmaceutical Education & Research, Kolkata, India, E-mail: mythri059@gmail.com

Received: February 03, 2017; **Accepted:** March 28, 2017; **Published:** April 05, 2017

Abstract

Acute myeloid leukaemia (AML) is a life threatening hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have didn't considerably improve clinical outcomes. Over the past decade, proteasome inhibition has been incontestable to be a good therapeutic strategy in many medicine malignancies. Proteasome inhibitors, like bortezomib and carfilzomib, became mainstays of treatment for myeloma and mantle cell malignant neoplastic disease. In light-weight of this success, there has been a surge of literature exploring each the role of the proteasome and also the effects of proteasome inhibition in acute myeloid leukaemia. Pre-clinical studies have incontestable that proteasome inhibition disrupts proliferative cell sign pathways, exhibits cytotoxic synergism with different chemotherapeutics and induces autophagy of cancer-related proteins. Meanwhile, clinical trials incorporating bortezomib into combination therapy regimens have reported a variety of responses in AML patients, with complete remission rates. In a trial to focus additional investigation into this space, these recent studies and their findings are reviewed here.

Keywords: *Acute myeloid leukaemia; Blood cancer; Pre-clinical studies; Proteasome; Haematological malignancy*

Introduction

Acute myeloid leukaemia (AML) could be a fatal medical specialty malignancy characterised by the growth accumulation of immature myeloid cells [1] (Figure 1). The quality of care therapy regime for AML was established over thirty years past and remains for the most part unchanged nowadays. This regime, consisting of cytarabine and an anthracycline, achieves complete remission in up to eighty fifth of adults who square measure sixty years older or younger; but, most patients can relapse at intervals three years [2-5]. In spite of salvage choices together with further therapy and allogeneic organic process somatic cell transplantation the prognosis for patients United Nations agency relapse is uniformly poor, with 5-year overall survival chances starting from four to forty sixth [6]. In old patients (>60 years), the prognoses for every primary and relapsed AML unit of measurement is even worse. Thus, there's a transparent and emerging want for the event of recent therapeutic approaches for acute myeloid leukaemia [7-12]. One promising molecular target is that the proteasome, an outsized multimeric super molecule advanced that degrades excess or broken proteins. As such, the proteasome has AN integral role in an exceedingly kind of cellular processes, as well as cell survival, cell sign and cell-cycle progression.




FIG. 1. Acute myeloid leukaemia without maturation.

Malignant cells are extremely hooked in to enlarged super molecule production and degradation, suggesting that they'd be sensitive to proteasome inhibition. Indeed, proteasome inhibition could be a mainstay of medical aid in bodily fluid malignancies [13-20]. Proteasome inhibitors, like bortezomib and carfilzomib, are currently incorporated into customary of care regimens for many patients with myeloma (MM) and different lymph cell neoplasms, and this approach has yielded considerably improved clinical responses and OS for these patients. Proteasome inhibition has additionally shown effectualness within the initial treatment of mantle cell malignant neoplastic disease (MCL) 10 and within the relapsed/refractory setting for different non-Hodgkin lymphomas, like vesicle malignant neoplastic disease [21].

Several pre-clinical and early stage clinical trials work the role of the proteasome and proteasome inhibition in AML has shown promising results. During this review, we have a tendency to discuss these studies and their findings [22-29].

The mission of The Leukaemia & Lymphoma Society is to cure leukaemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS exist to find cures and ensure access to treatments for blood cancer patients [30-35]. LLS exist to search out cures and guarantee access to treatments for blood cancer patients. This society mostly works to make sure access to treatments for all type of blood cancer patients [36-41]. Leukaemia Cancer Society is premises in 1994 when leukaemia sufferers John Triteos and Anna Georgiou, who needed bone marrow transplants to save their lives, began making a desperate appeal for bone marrow donors to come forward. The leukaemia Cancer Society is devoted to making sure that additional folks with blood cancer survive, have the simplest potential quality of life which their families and carers get the support they have. LCS is passionate and caring volunteers, donors and members for most of cancer patients [42].

There are conferences which are going to be held on Hematology to promote the standard medical research on various diseases like anaemia and leukaemia [43-53]. In which Clinical and Experimental Hematology is going to be held on October 16-17, 2017 at Rome, Italy. Which has been designed with many interesting and informative scientific sessions; it includes

all possible Clinical and Experimental aspects of Hematology research [54-60]. World Haematologists Congress is going to be held on May 08-09, 2017 Barcelona, Spain. The main theme of the conference is to bring the all the Hematology experts on one platform to present or execute their research experience or research works on blood research & hematologic diseases [60-69]. International Conference on Blood Cancer & Treatment is going to be held on June 26-27, 2017 London, UK. Which is mainly focuses on the better treatment criteria's of the blood cancers like leukaemia, lymphoma and myeloma [70].

There square measure conferences that square measure aiming to be remained haematology to market the quality medical analysis on varied diseases like anaemia and cancer. During, which Clinical and Experimental Haematology goes to be remained Oct 16-17, 2017 at Rome, Italy [71-78]. That has been designed with several fascinating and informative scientific sessions; it includes all attainable Clinical and Experimental aspects of haematology analysis [79-81]. World Haematologists Congress goes too remained could 08-09, 2017 port, Spain. the most theme of the conference is to bring the all the haematology consultants on one platform to gift or execute their analysis expertise or analysis works on blood analysis; haematological diseases [82-89]. International Conference on Blood Cancer; Treatment goes to be remained June 26-27, 2017 London, UK. That is principally focuses on the higher treatment criteria's of the blood cancers like cancer, malignant neoplastic disease and malignant tumor [90].

Recently an article title "Characterization of Complex Chromosomal Rearrangements in Acute Myeloid Leukaemia: FISH and Multicolor FISH Add Precision in Defining Abnormalities Associated with Poor Prognosis" in Journal of Blood Research & Hematologic Diseases explains the trending disorder in many individuals. The identification of specific chromosome abnormalities in Acute Myeloid Leukaemia (AML) is the important for the stratification of patients into the appropriate treatment protocols [91-97]. As it is growing in gift world there area unit large range of specialists during this field to gauge or examine the anaemic patients to create higher quality medication to forestall the diseases with low price. There area unit few specialists like Alan M. Miller UN agency helps individuals by sharing his analysis expertise within the style of analysis articles and editorial to form the individuals responsive to endangerous diseases like leukaemia, Bone marrow transplantation etc. [98]. His recently printed editorial in Journal of Blood analysis; haematological Diseases can justify regarding the recent importance of Bone Marrow Transplantation, Leukaemia, Lymphoma, and favouring the employment of haematological diseases [99].

In current days childers are affected to major diseases like cancers, etc. once a toddler is littered with a significant, typically fatal, no heritable malady like cancer or cancer, or an inherited disorder with poor prognosis, and therefore is hospitalized for long periods of your time, the uncertainty and unpredictability keep oldsters in an exceedingly state of constant anxiety that's laborious to trot out and tough to manage whereas maintaining a well-balanced behaviour [100-114]. Luisa M. Massimo is Associate in nursing knowledgeable within the field of medicine, Health management, Oncology, paediatric Hematology/Oncology, Bioethics, psychological science and quality of life. She has explored her concepts on cancer and cancers to aware the foremost of individuals UN agency are suffering with them [115-121]. She even performed several analysis works and printed novel and innovative works on numerous sorts of blood cancers to beat the likelihood of death or major facet effects of these diseases. At the moment she has retired and serving to individuals through her expertise above all filed to urge attentive to several researchers additionally individuals [122-132].

Conclusion

These studies highlight the vital role of the proteasome in AML biology and counsel that proteasome inhibition could also be an efficient therapeutic possibility in AML [133-140]. To rose perceive the molecular effects and clinical outcomes of proteasome inhibition, additional investigation is required are many areas. All this data will be accessed in open access health care journal publications that show the novel and innovative techniques to cure the anaemia and additionally it enclosed the recent discoveries of analysis's that are going down in current research field [141-148]. There area unit such a large amount of consultants United Nations agency were sharing their views and suggestions through the open access literature which may be accessed by tired order attain data on anaemia. However, anaemia is major blood connected disorder in European countries, they're developing several innovative techniques to beat the matter of anaemia and later the analysis work goes to be serious to coin the novel medicines and techniques to diagnose the anaemia patient's with previous implementations [149-150].

REFERENCE

1. Malshe AG. Hydrogen ion/Proton Dynamics: A Possible Therapeutic Approach in Malignancy Treatment. *J Clin Exp Oncol.* 2016; 5:1.
2. Shin DG. A Methylation Profile of Circulating Cell Free DNA for the Early Detection of Gastric Cancer and the Effects after Surgical Resection. *J Clin Exp Oncol.* 2016;5:1.
3. Romeira D. Tumor Infiltrating Lymphocytes and Axillary Lymph Node Positivity: A Systematic Review. *J Clin Exp Oncol.* 2016; 5:2.
4. Norollahi SE. The Role of MicroRNAs in Cancer Progression. *J Clin Exp Oncol.* (2016);5:2.
5. Kumar R. Quantum Magnetic Resonance Therapy: Targeting Biophysical Cancer Vulnerabilities to Effectively Treat and Palliate. *J Clin Exp Oncol.* 2016;5:2.
6. Parvathi MVS. Micro RNA-142-5p Profile as a Predictor of Tumor Markers Regulation in Different Histological Grades of Human Breast Carcinoma. *J Clin Exp Oncol.* 2016;5:2.
7. Xu Y. Early Changes in 2D-Speckle-Tracking Echocardiography may Predict a Decrease in Left Ventricular Ejection Fraction in Lymphoma Patients Undergoing Anthracycline Chemotherapy: A Pilot Study. *J Clin Exp Oncol.* 2015;4:1.
8. Mushtaq M. Choriocarcinoma Presenting as Intracerebral Haemorrhage and No Evident Primary: Rare Presentation. *J Clin Exp Oncol.* 2015;4:1.
9. Kotb AF, Attia D .Correlation between the Presentation of Renal Cell Carcinoma and its Prognosis. *J Clin Exp Oncol.* 2015;4:1.
10. Karimi A. Challenges in Diagnose and Management of Ameloblastic Carcinoma: A Report of Three Cases. *J Clin Exp Oncol.* 2015;4:2.
11. Yousef YA. External Beam Radiation Therapy for Retinoblastoma Resistant to Chemotherapy and Focal Treatment: Outcome and Predictive Factors. *J Clin Exp Oncol.* 2015;4:2.
12. Kuperman VY. Evaluation of Automatic and Manual Contouring of Cranial Structures. *J Clin Exp Oncol.* 2015;4:3.
13. Brown MA. Developing Research Networks to Enhance Cross-Mentoring and Representation of Women in Clinical and Experimental Oncology. *J Clin Exp Oncol.* 2015;4:3.
14. Slaoui W. Unusual Ulcerated Nodules of Scalp with Histological Proof of Cutaneous Metastasis Derived from Prostate Cancer: Report of a Case *J Clin Exp Oncol.* 2015;4:3.

15. Mandal S. A Case of Multiple Myeloma Presenting with Plasmacytoma of Body of Sphenoid Bone: A Case Report *J Clin Exp Oncol.* 2015;4:3.
16. Der EM. Malignant Tumours of the Female Genital Tract: A 10-Year Histopathological Review at the Korle-Bu Teaching Hospital (2002-2011). *J Clin Exp Oncol.* 2015;4:4.
17. Gong Z. Effect of Vaccination with Different Types and Dosages against a Very Virulent Marek's Disease Virus Strain. *J Clin Exp Oncol.* 2015;4:4.
18. Brahmabhatt MM. Highly Complex Chromosomal Rearrangements in Patients with Chronic Myeloid Leukemia: An Indian Experience. *J Clin Exp Oncol.* 2015;4:4
19. Tilakaratne WM. Demographic and Histopathological Differences of Oral Squamous Cell Carcinoma; Analysis of 4394 Cases from Sri Lanka. *J Clin Exp Oncol.* 2015;4:4.
20. Atalay C. Impact of Loco-Regional Under-treatment in Elderly Patients with Early Breast Cancer (Protocol Yameka-09sdl); Multi-Centric Retrospective Cohort Study. *J Clin Exp Oncol.* 2014;3:1
21. Tsvetkov Ch, Gorchev G, Tomov S, et al. Survival Rate after Individualized Approach in Treatment of Vulvar Cancer: A Ten- Year Single Institution Experience. *J Clin Exp Oncol.* 2016;5:3.
22. Ashourpour M, Namdar A, Kheshtchin N, et al. Olive Leaf Extract Reduces Myeloid-Derived Suppressor Cells, and Modulates the Function of Residual Cells in Experimental Model of Melanoma. *J Clin Exp Oncol.* 2016;5:3.
23. Decker J, Jain G, Kießling T, et al. Loss of the Tumor Suppressor NKX3.1 in Prostate Cancer Cells is Induced by Prostatitis Related Mitogens. *J Clin Exp Oncol.* 2016;5:3.
24. Panucci RKI, Mellitto A, Oliveira CR, et al. In vitro Study of Anti-Leukemic Potential of Ursolic Acid in Jurkat Cell Line. *J Clin Exp Oncol.* 2016;5:3.
25. Huang H, Wan F, Ding Sg, et al. Prognostic Significance of KAI1/CD82 and its Relation Tod2-40 Labeled Lymphatic Vessel Invasion (LVI) and Lymphatic Vessel Density (LVD) in Esophageal Squamous Cell Carcinoma (ESCC). *J Clin Exp Oncol.* 2016;5:3.
26. Kerivan L, Reintgen M, Reintgen E, et al. Male Breast Cancer. *J Clin Exp Oncol.* 2016;5:4.
27. Babayouski R, Ortega V, Mendiola C, et al. Colonic Adenocarcinoma in a Patient with Velo Cardio Facial Syndrome (VCFS) and 22q11.2 Microdeletion. *J Clin Exp Oncol.* 2016;5:4.
28. Poljsak B. NAD⁺ in Cancer Prevention and Treatment: Pros and Cons. *J Clin Exp Oncol.* 2016;5:4.
29. Tekin C, Oğuzkan SB, Ozaslan M, et al. MDM2 Gen Polymorphisms at Acute Myeloid Leukemia Patients. *J Clin Exp Oncol.* 2016;5:4.
30. Farzanfar H, Motalleb G, Maghsoudi H. VEGF Expression Evaluation in Patients with Esophageal Cancer by using Reverse Transcriptase Real- Time Polymerase Chain Reaction. *J Clin Exp Oncol.* 2016;5:6.
31. Gumustas SA, Yilmaz I, Isyar M, et al. Is it Possible to Expedite Studies on the Effects of Pharmacological Agents on Primary Cell Cultures Obtained from High-grade Fibular Osteosarcoma? *J Clin Exp Oncol.* 2016;5:6.
32. Clemente N, Alessandrini L, Giorda G, et al. Enterouterine Fistula as Initial Presentation of Advanced Endometrial Cancer: Description of a Rare Case and Review of the Literature. *J Clin Exp Oncol.* 2016;5:6.
33. Hayashibara N, Ogawa T, Tsuji E, et al. Parathyroid Carcinoma Coincident With Neurofibromatosis Type 1. *J Clin Exp Oncol.* 2016;5:6.
34. Epstein-Barr Virus Associated Lymphoepithelioma-Like Carcinoma of the Esophagogastric Junction and Stomach: A Case Report and Review of the Literature. *J Clin Exp Oncol* 2016;5:6.

35. Malone MV, Mejía EH, Hu G. Lack of Association between Angiogenin (AGN) KO Mice with Improvement in Muscle Strength, Resistance, but Decreased in Chances of Tumorigenesis: Observational Study. *J Clin Exp Oncol.* 2016;6:1.
36. Dombi P, Andrikovics H, Illés Á, et al. Thromboembolic Events in Polycythaemia Vera Patients: An Audit of the Hungarian Philadelphia Negative Chronic Myeloproliferative Neoplasia Register. *J Clin Exp Oncol.* 2016;6:1.
37. Suyama K, Miura Y, Takano T, et al. Chemotherapy for Patients with Renal Dysfunction. *J Clin Exp Oncol.* 2017;6:1.
38. Hassoun HK, Al-Essawi S, Tiraihi TA, et al. Can Medulloblastoma be Presented with Primary Diffuse Leptomeningeal Gliomatosis? Case Report and Literature Review. *J Clin Exp Oncol.* 2017;6:1.
39. Rodrigues C, Romeira D, Pinto M, et al. Immunosurveillance in Colorectal Carcinomas with Microsatellite Instability. *J Clin Exp Oncol.* 2017;6:1.
40. Chalupova L, Halupova L, Zakovska A, et al. CTRP1: A Molecular Link between Obesity and Hypertension . *J Mol Biomark Diagn.* 2016;7: 289.
41. Ali SA. Use of Smokeless Tobacco in Medical Students and Hypertension. *Occup Med Health Aff.* 2016;4:240.
42. Stoicescu M. The Risk of Sudden Decrease of Severe Arterial Hypertension . *J Clin Exp Cardiol.* 2016;7:460.
43. Chauhan R, Parihar AKS, Chauhan S. Hypertension and the Aged. *J Gerontol Geriatr Res.* 2016;S5:002.
44. Pagano D, Barbieri L, Gruttadauria S. Portal Hypertension Model in Pigs. *J Clin Exp Transplant.* 2016;1:e101.
45. Aberha M, Gebeyehu A, Ayano G. Prevalence and Factors Associated with Anxiety among Patients with Hypertension on Follow Up at Menelik- II Referral Hospital, Addis Ababa Ethiopia. *J Psychiatry.* 2016;19:378.
46. Trailokya A. Will Azilsartan - An Eight ARB Bring Paradigm Shift in Hypertension Management Practices in India? *Cardiovasc Pharm Open Access.* 2016;5:189.
47. Li M, Zhang L, Shi J. To Live Long, Eat Less Salt: Salt Intake Reduction Promotion and Hypertension Control in China. *Health Care: Current Reviews.* 2016;4:169.
48. Soltani HM, Namayandeh SM, Latifeh J, et al. The Effect of Fasting During Ramadan on Blood Pressure in Patients with Controlled and Mild Hypertension. *J Hypertens.* 2016;5:227.
49. Sarfaraz S, Farooq N, Ashraf N, et al. Non Pharmacological Use of *Daucus carota* Juice (Carrot Juice) as Dietary Intervention in Reducing Hypertension. *Enz Eng.* 2016;5:147.
50. Berezin AE. Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression? *Clin Med Biochemistry Open Access.* 2016;2:114.
51. Manolis A, Doumas M. Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol . *J Hypertens.* 2016;5:226.
52. Lv Y, Lau WY, Deng J, et al. Non-Hypersplenism Causes of Peripheral Cytopenias in Patients with Cirrhotic Portal Hypertension: A Review. *J Hypertens.* 2016;5:223.
53. Li X, Qiao Y, Li Y, et al. Angiotensinogen M235T, β 2 Adrenergic Receptor Arg16Gly and Aldosterone Synthase C-344T Gene Polymorphisms and Essential Hypertension among Han Population Living at High Altitude in China. *J Hypertens.* 2016;5:222.
54. Abdel-hamid ER, Mohammed EA, Aleraky AZ, et al. Association of Angiotensin Converting Enzyme Gene Polymorphism and Possible High Risk Factors with Essential Arterial Hypertension in Egyptian Patients. *Mol Biol.* 2016;5:165.

55. EL-Adawy NM, Helmy AK, Ismail TT, et al. Fibroblast Growth Factor-23: A Possible Cause of Pulmonary Hypertension and Left Ventricle Hypertrophy in Hemodialysis Patients. *J Clin Exp Cardiol*. 2016;7:449.
56. Feyh A, Bracero L, Lakhani HV, et al. Role of Dietary Components in Modulating Hypertension. *J Clin Exp Cardiol*. 2016;7:433.
57. Guney F, Bozkurt B, Paksoy Y. Intracranial Hypertension in Behcet Disease: A Case Report. *J Clin Case Rep*. 2016;6:748.
58. Bogari DF, Bakalka GT, Hazzazi LW, et al. The Prevalence of Hypertension in Endodontic Clinics: A Pilot Study. *Dentistry*. 2016;6:370.
59. Silva RP, Sousa NRP, Costa PSC, et al. Who is the Patient with Suspected White Coat Hypertension? . *J Clin Exp Cardiol*. 2016;7:428.
60. Aissa S, Mezghani S, Benzarti W, et al. Prognosis Evaluation of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension. *J Pulm Respir Med*. 2016;6:328.
61. Li H. Hypertension Management in Primary Care in China: Still a Long Way to Proceed. *J Gen Practice*. 2016;4:238.
62. Tsabang N, Fongzossie E, Donfack D, et al. Comparative Study of Epidemiological and Anthropological Aspects of Diabetes and Hypertension in Cameroon. *Forest Res*. 2016;5:165.
63. Dash SK, Kulkarni V, Sahoo RK, et al. Idiopathic Pulmonary Hypertension Induced Thrombocytopenia - A Case Report. *J Pulm Respir Med*. 2016;6:322.
64. Huckabay L, Reynolds GL, Fisher DG, et al. Hypertension in a Low-income and Homeless Community Sample. *J Community Med Health*. 2016;6:399.
65. Gonzalez-Aguirre AJ, Lin O, Cho C, et al. Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and “Miliary” Liver Lesions: A Case Report. *J Gastrointest Dig Syst*. 2016;6:390.
66. Kamal I, Hamdy R, Mohamed N. Kidneys: The Victim Of Hypertension: Review. *J Nephrol Ther*. 2015;6:231.
67. Mussa BM, Abdulllah Y, Abusnana S. Prevalence of Hypertension and Obesity among Emirati Patients with Type 2 Diabetes. *J Diabetes Metab*. 2016;7:638.
68. Viggiano A, Passavanti MB, Zagaria G, et al. Anti-Hypertensive Treatments and Hypertension- Associated Hypoalgesia Evaluated by Auto-Algometry. *J Anesth Clin Res*. 2015;6:589.
69. Bos AJG, Jorge LB, Navarro JHN, et al. Comparing the Prevalence and Drug Treatment Rates of Diabetes, Hypertension and Dyslipidemia between Japan and Brazil, using 2013 National Health Surveys. *J Clin Diabetes Pract*. 2015;1:103.
70. Yunfu Lv, Han XY, Gong X, et al. Analysis of Peripheral Blood Cells Due to Adults Posthepatic Cirrhotic Portal Hypertension and Their Postoperative Prognosis. *J Hyperten*. 2015;4:210.
71. Al-Hamdan NA. Isolated Systolic Hypertension among Adults in Saudi Arabia: Prevalence, Risk Factors, Predictors and Treatment - Results of a National Survey. *Epidemiology (sunnyvale)*. 2015;5:206.
72. Lerman MJ, Hinton S, Aronoff R. Post Kidney Transplant Refractory Hypertension and Bilateral Native Nephrectomy. *J Kidney*. 2015;1:107.
73. Safdar Z, Thakur A, Singh S, et al. Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension. *J Pulm Respir Med*. 2015;5:295.
74. Ashoor I. Pediatric Hypertension: A Primer for the Busy Primary Care Provider. *J Nephrol Ther*. 2015;5:218.

75. Mutlu E, Ilhan N, Ilhan N, et al. Comparative Effectiveness of Novokinin, Perindopril and Losartan on Blood Pressure, Adma, Nadph Oxidase and Rho Kinase at Renal Tissue in L-Name and Salt Induced Hypertension. *Clin Exp Pharmacol*. 2015;5:197.
76. Herbert S, Tulloh RMR. Treatment of Pulmonary Hypertension in Down's Syndrome. *J Genet Syndr Gene Ther*. 2015;6:273.
77. Roever L, Borges ASR. Pulmonary Hypertension and Exercise Training: Evidence Based Studies. *Lung Dis Treat*. 2015;1:e103.
78. Al-Saloos H, Saeed S. Rare Case of Bilateral Superior Vena Cava, Persistent Left Superior Vena Cava Draining to Coronary Sinus, Absent Bridging Vein, Interrupted Inferior Vena Cava with Azygos Vein Continuation to Right Superior Vena Cava, Situs Inversus and Pulmonary Hypertension in a Neonate: A Case Report. *Pediat Therapeut*. 2015;5:i110.
79. Strażyńska A, Hoffmann K, Bryl W, et al. The Relationship between Serum Apelin Concentration and Selected Anthropometric Parameters, Serum Lipids and Carotid Intima-Media Thickness in Young Subjects with Primary Arterial Hypertension. *J Metabolic Syndr*. 2015;4:185.
80. Plácido R, Martins S, Marques JS, et al. Predictors of Functional Capacity in Patients with Pulmonary Hypertension. *J Pulm Respir Med*. 2015;5: 290.
81. Rajekar H. Complication of Cirrhosis Portal Hypertension: A Review. *J Liver*. 2015;4:188.
82. Roever L. High-Sensitivity C-Reactive Protein, Hypertension and Stroke: Cause and Effect or Simple Association?. *InternMed*. 2015;5:e102.
83. Sun Y, Wu J, Li X. Pulmonary Arterial Hypertension from Hepatic HHT. *InternMed*. 2015;5:109.
84. Aronow WS. 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Guidelines on Treatment of Hypertension in Patients with Coronary Artery Disease. *J Hypertens*. 2015;4:e113.
85. Jiangyan C, Zhengliqiang L, Lixiaodong M. Association among Systolic Blood Pressure Variation, Inflammation and Arterial Rigidity in Essential Hypertension. *J Hypertens (Los Angel)*. 2015;4:207.
86. Padda RS, Shi Y, Lo CS, et al. Angiotensin-(1-7): A Novel Peptide to Treat Hypertension and Nephropathy in Diabetes?. *J Diabetes Metab*. 2015;6:615.
87. Rovedder PME, Andrade FP, Dalcin PDTR. Pulmonary Hypertension and Pulmonary Disorders in Cystic Fibrosis. *Cardiovasc Pharm Open Access*. 2015;4:158.
88. Vadapalli S, Chaitra KL, Satyanarayana ML, et al. Variants of PGIS and PPAR γ in Idiopathic Pulmonary Arterial Hypertension. *J Clin Med Genomics*. 2015;3:130.
89. Srinivasamurthy BC. Burden and Determinants of Hypertension in Rural Pondicherry, India. *J Clin Med Genomics*. 2015;3:127.
90. Nikitin VA, Gosteva EV, Mishina YV, et al. Concor AM Therapy in Patients with Chronic Obstructive Pulmonary Disease and Concomitant Arterial Hypertension. *Biol Med (Aligarh)*. 2015;7:246.
91. Kobata K, Nabetani M, Yutaka N, et al. Experiences of Therapeutic Hypothermia Therapy on Six Cases with Persistent: Pulmonary Hypertension and Moderate to Severe Hypoxic Ischemic Encephalopathy using Inhaled Nitric Oxide Therapy. *J Neonatal Biol* 2015;4:198.
92. Basturk T, Pamukcu Ö, Koc Y, et al. A Case Report of Thrombotic Microangiopathic Malignant Hypertension. *J Hypertens* 2015;4:205.

93. Rodríguez ÁD, De Abajo Larriba AB, Rodríguez EM, et al. Does Self-measurement of Blood Pressure (SMBP) Contribute to Improve the Degree of Hypertension Control? *Fam Med Med Sci Res* 2015;4:183.
94. Wan G, et al. Hierarchical ZnO nanostructures derived from zn-al layered double hydroxides and their photocatalytic activity. *J Nanomater Mol Nanotechnol.* 2014;3:4.
95. Castelli F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. *Int J Pharm.* 2005;304:231-8.
96. Kumar D. Some mechanical properties of carbon nanotubes heterojunctions. *J Nanomater Mol Nanotechnol.* 2014;3:3
97. Hung LC. An improved method for the preparations of nanostructured lipid carriers containing heat sensitive bioactives. *Colloids Surf B: Biointerf.* 2011;87:180-186.
98. Faheim AS. Effect of Zn substitution on the characterization of cobalt ferrite nano particles prepared co-precipitation method. *J Nanomater Mol Nanotechnol.* 2014;4:1.
99. Sato K. Crystallization behaviour of fats and lipids-a review. *Chem Eng Sci.* 2001;5:2255-2265.
100. Vaze OS. Pharmaceutical nanocarriers (liposomes and micelles) in cancer therapy. *J Nanomed Nanotechnol.* 2016;7:e138
101. Álvarez-Bautista A. Poly(N-Isopropylacrylamide-Co-Acrylic Acid) smart nanocarriers for drug release: a study of theophylline delivery. *J Mol Genet Med.* 2015;9:196
102. Dall'Agnol FF, den Engelsen D. Field emission simulations of carbon nanotubes and graphene with an atomic model. *J Nanomater Mol Nanotechnol.* 2014;3:4.
103. Fadel M. Antitumor efficiency of doxorubicin loaded in liposomes and poly ethylene glycol coated ferrofluid nanoparticles. *J Nanomater Mol Nanotechnol.* 2015;4:1
104. Kumar R and Lal S. Synthesis of organic nanoparticles and their applications in drug delivery and food nanotechnology: a review. *J Nanomater Mol Nanotechnol.* 2014;3:4.
105. Li C, et al. Development and Validation of a Method for Determination of Encapsulation Efficiency of CPT-11/DSPE-mPEG2000 Nanoparticles. *Med chem (Los Angeles).* 2016;6:345-348.
106. Heidari A. Pharmaceutical and Analytical Chemistry Study of Cadmium Oxide (CdO) Nanoparticles Synthesis Methods and Properties as Anti- Cancer Drug and its Effect on Human Cancer Cells. *Pharm Anal Chem Open Access.* 2016;2:113.
107. Heidari A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double-Standard DNA/RNA-Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh2O3) Nanoparticles as Anti-Cancer Drugs for Cancer Cells' Treatment. *Chemo Open Access.* 2016;5: e129.
108. Kumar B, et al. Aqueous Phase Lavender Leaf Mediated Green Synthesis of Gold Nanoparticles and Evaluation of its Antioxidant Activity. *Biol Med (Aligarh).* 2016;8: 290.
109. Stael C and Cumbal L. Optimized Synthesis of Multicomponent Nanoparticles for Removing Heavy Metals from Artificial Mine Tailings. *Biol Med (Aligarh).* 2016;8: 288.
110. Heidari A. Novel and Stable Modifications of Intelligent Cadmium Oxide (CdO) Nanoparticles as Anti-Cancer Drug in Formation of Nucleic Acids Complexes for Human Cancer Cells' Treatment. *Biochem Pharmacol (Los Angel).* 2016;5:207.
111. Stab J. Flurbiprofen-loaded Nanoparticles Can Cross a Primary Porcine In vitro Blood-brain Barrier Model to Reduce Amyloid-β42 Burden. *J Nanomedine Biotherapeutic Discov.* 2016;6:140.

112. Gandhi H, Khan S. Biological Synthesis of Silver Nanoparticles and Its Antibacterial Activity. *J Nanomed Nanotechnol.* 2016;7:366.
113. Murgueitio E. Synthesis of Iron Nanoparticles using Extracts of Native Fruits of Ecuador, as Capuli (*Prunus serotina*) and Mortiño (*Vaccinium floribundum*). *Biol Med (Aligarh).* 2016;8:282.
114. AbouAitah KEA. Mesoporous Silica Materials in Drug Delivery System: pH/Glutathione- Responsive Release of Poorly Water-Soluble Pro-drug Quercetin from Two and Three-dimensional Pore-Structure Nanoparticles. *J Nanomed Nanotechnol.* 2016;7:360.
115. Sivaramasamy E. Enhancement of Vibriosis Resistance in *Litopenaeus vannamei* by Supplementation of Biomastered Silver Nanoparticles by *Bacillus subtilis*. *J Nanomed Nanotechnol.* 2016;7:352.
116. AbouAitah KEA. pH-controlled Release System for Curcumin based on Functionalized Dendritic Mesoporous Silica Nanoparticles. *J Nanomed Nanotechnol.* 2016;7:351.
117. Kumar P. Synthesis of Dox Drug Conjugation and Citric Acid Stabilized Superparamagnetic Iron-Oxide Nanoparticles for Drug Delivery. *Biochem Physiol.* 2016;5:194.
118. Vinoda BM. Photocatalytic Degradation of Toxic Methyl Red Dye Using Silica Nanoparticles Synthesized from Rice Husk Ash. *J Environ Anal Toxicol.* 2015;5:336.
119. El-Hussein A. Study DNA Damage after Photodynamic Therapy using Silver Nanoparticles with A549 cell line. *J Nanomed Nanotechnol.* 2016;7:346.
120. Yasir M. Haloperidol Loaded Solid Lipid Nanoparticles for Nose to Brain Delivery: Stability and In vivo Studies. *J Nanomedic Nanotechnol.* 2015;S7:006.
121. Hajiyeva FV. Luminescent Properties of Nanocomposites on the Basis of Isotactic Polypropylene and Zirconium Dioxide Nanoparticles. *J Nanomedic Nanotechnol.* 2015;S7:003.
122. Shareena Dasari TP. Antibacterial Activity and Cytotoxicity of Gold (I) and (III) Ions and Gold Nanoparticles. *Biochem Pharmacol (Los Angel).* 2015;4:199.
123. Prasad CH. Catalytic Reduction of 4-Nitrophenol Using Biogenic Silver Nanoparticles Derived from Papaya (*Carica papaya*) Peel extract. *Ind Chem Open Access.* 2015;1:104.
124. Vincze Gy. Nanoheating without Artificial Nanoparticles. *Biol Med (Aligarh).* 2015;7:249.
125. López T, et al. Ag/TiO₂-SiO₂ Sol Gel Nanoparticles to use in Hospital-Acquired Infections (HAI). *J Material Sci Eng.* 2015;4:196.
126. Abdellatif AAH. Targeting of Somatostatin Receptors using Quantum Dots Nanoparticles Decorated with Octreotide. *J Nanomed Nanotechnol.* 2015;S6:005.
127. Mehrotra A, Pandit JK. Preparation and Characterization and Biodistribution Studies of Lomustine Loaded PLGA Nanoparticles by Interfacial Deposition Method. *J Nanomed Nanotechnol.* 2015;6:328.
128. Singh T, Jain S. Removal of Organics and Metal Ion Nanoparticles from Synthetic Wastewater by Activated Sludge Process (ASP). *J Civil Environ Eng.* 2015;5:182.
129. Turani M. Regeneration of Limbal Stem Cells in the Presence of Silver and Gold Nanoparticles. *J Environ Anal Toxicol.* 2015;5:318.
130. Andocs G. Nanoheating without Artificial Nanoparticles Part II. Experimental Support of the Nanoheating Concept of the Modulated Electro-Hyperthermia Method, Using U937 Cell Suspension Model. *Biol Med (Aligarh).* 2015;7:247.

131. Maithri G, Manasa B, Vani SS, et al. Computational Drug Design and Molecular Dynamic Studies-A Review. *Biomedical Data Mining* 2016;5: 123.
132. Olson JL. Intraocular biocompatibility of gold-nanoparticles. *J Nanomater Mol Nanotechnol.* 2013;2:2.
133. Pan SY. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. *Eur J Pharmacol.* 2006;552:170-175.
134. Wang H. Hydrothermal growth of aligned ZnO nanorods along the seeds prepared by magnetron sputtering and its applications in quantum dots sensitized photovoltaic cells. *J Nanomater Mol Nanotechnol.* 2013;2:2
135. Lombardi Borgia S. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and piezoelectric spectroscopy. *J Control Release.* 2005;110:151-163.
136. Hu W. Fibroblast behavior on PMMAEA and PMMAEA-collagen films and nanofibers. *J Nanomater Mol Nanotechnol.* 2013;2:5.
137. Feng F. Preparation, characterization, and biodistribution of nanostructured lipid carriers for parenteral delivery of bifendate. *J Microencapsul.* 2011;28:280-285.
138. Wiley TS. H1R antagonists for brain inflammation and anxiety: targeted treatment for autism spectrum disorders. *J Pharm Drug Deliv Res.* 2015;4:3.
139. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. *Int J Pharm.* 2008;346:124-132.
140. Nair AK. Development and comparative assessment of hydrocolloid based against wax based gastro retentive bilayered floating tablet designs of atorvastatin calcium using QBD approach. *J Pharm Drug Deliv Res.* 2015;4:3.
141. Silver RT, Hasselbalch HC. Optimal Therapy for Polycythemia Vera and Essential Thrombocythemia: A Different Perspective. *J Blood Res Hematol Dis* 2015;1:1.
142. Massimo LM. Caring for a Sick Child. *J Blood Res Hematol Dis* 2015;1:1.
143. Maeda Y, Okamoto A, Kawaguchi S, et al. Relationship between Cellular Senescence and Redox Potential on Adult T-Cell Leukemia Cells. *J Blood Res Hematol Dis* 2016;1:1.
144. Paulsrud C, Hasselbalch HC, Bjerrum OW. Autoimmune Thyroid Disease in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms Treated with Interferon-Alpha. *J Blood Res Hematol Dis* 2016;1:1.
145. Sadras T, Andrea RJD, White DL. The Role of Wnt/ β -Catenin Signaling in Normal and Malignant Hematopoiesis. *J Blood Res Hematol Dis* 2016;1:1.
146. Vassilakopoulos TP, Papageorgiou SG. Recent Advances in Hodgkin Lymphoma. *J Blood Res Hematol Dis* 2016;1:2.
147. Trivedi PJ, Patel DM, Brahmabhatt MM, et al. Characterization of Complex Chromosomal Rearrangements in Acute Myeloid Leukemia: FISH and Multicolor FISH Add Precision in Defining Abnormalities Associated with Poor Prognosis. *J Blood Res Hematol Dis* 2016;1:2.
148. Khan AA, Wani ZA, Kochak T, et al. EHPVO and Splanchnic Vein Thrombosis. *J Blood Res Hematol Dis* 2016;1:2.
149. Rasika S, Satyam A, Anil H, et al. Efficiency of Pre-Storage Leukoreduction of Red Cells: A Double Blind Quality Control Method. *J Blood Res Hematol Dis* 2016;1:2.
150. Jimmy EO, Udo ES. Timely Dosage Dependent Ethanolic Extract of *Mangifera Indica* Promotes Blood Cells Development and Weight Gain. *J Blood Res Hematol* 2016.